Global Autism
Spectrum Disorder Therapeutics Market, by Drug Type (Aripiprazole, Risperidone,
Melatonin, CM-AT, Bumetanide, and Balovaptan), by Age Group (Child and Adult),
by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online
Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific,
Middle East, and Africa) was valued at US$
2,285.5 million in 2019 and is projected to exhibit a CAGR of 10.9% over
the forecast period (2019 - 2027).
Increasing investigational
research and funding support for pharmacogenomics-based drug discovery is a
major factor driving growth of the autism spectrum disorder therapeutics
market. Various organizations are
focused on receiving approvals to investigate novel drugs for the treatment of
ASD. For instance, in January 2018, Roche announced that the U.S. Food and Drug
Administration (FDA) granted breakthrough therapy designation for its
investigational oral medicine balovaptan, a vasopressin 1a (V1a) receptor
antagonist for individuals with ASD. Balovaptan demonstrated potential to
improve social interaction and communication in people with ASD. Similarly, in
May 2018, the U.S. FDA granted fast track designation for Yamo Pharmaceuticals’
investigational drug L1-79, a tyrosine hydroxylase inhibitor intended to
diminish the socialization and communication symptoms in individuals with ASD.
L1-79 demonstrated potential to address an unmet medical need for treatment of
core symptoms of ASD.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2643
Increasing funding for the
research of ASD drugs is expected to contribute in the ASD therapeutics market
size. For instance, in June 2018, Innovative Medicines Initiative funded US$
132 million to a research grant titled Autism Innovative Medicine
Studies-2-Trials (AIMS-2-Trials), which is academically co-led by the Institute
of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London
and F. Hoffmann-La Roche, Basel. Manufacturers in the autism spectrum disorder
therapeutics market are focused on adopting collaboration and partnership
strategies to enhance their market share. For instance, in 2017 Servier
Laboratories Ltd. and Neurochlore announced signing of an exclusive licensing
agreement to develop and market bumetanide for pediatric autism in Europe.
Under this agreement, Servier Laboratories Ltd. will develop and market the
product in Europe and Neurochlore will retain these rights for the U.S. market.
Browse 146 Market Data Tables and
30 Figures spread through 308 Pages and in-depth TOC on "Global Autism
Spectrum Disorder Therapeutics Market, by Drug Type (Aripiprazole, Risperidone,
Melatonin, CM-AT, Bumetanide, and Balovaptan), by Age Group (Child and Adult),
by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online
Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific,
Middle East, and Africa) - Global Forecast to 2027"
Furthermore, government
organizations are focused on conducting workshops for parents and caregivers of
children with developmental disorders, which is expected to aid in the ASD
therapeutic market growth. For instance, a workshop jointly led by Pan American
Health Organization, World Health Organization, and Autism Speaks is organized
annually in the month of August in Buenos Aires, Argentina, to teach skills and
raise awareness about autism and its preventive measures.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/autism-spectrum-disorder-therapeutics-market-2643
Key Takeaways of the Autism
Spectrum Disorder Therapeutics Market:
The global autism spectrum
disorder therapeutics market is expected to witness a CAGR of 10.9% during the
forecast period (2019–2027), owing to increasing drug approvals,
investigational studies, and funding
Among drug type, the Aripiprazole
segment is expected to hold major revenue share in 2019-2027, owing to
increasing production of generics of Aripiprazole. For instance, in April 2015,
the U.S. Food and Drug Administration (FDA) approved the pharmaceutical
companies Alembic, Hetero Labs, Teva, and Torrent for manufacturing the generic
version of Bristol-Myers Squibb’s Abilify oral tablets.
Major players operating in the
global autism spectrum disorder therapeutics market include, F. Hoffmann-La
Roche AG, Neurim Pharmaceuticals, Inc., Yamo Pharmaceuticals LLC, Servier
Laboratories Ltd., Otsuka Holdings Co. Ltd., Curemark LLC, Oryzon Genomics
S.A., GW Pharmaceuticals Plc., Teva Pharmaceutical Industries Ltd., Zynerba
Pharmaceuticals Inc., Stalicla SA., Novartis AG, Pfizer, Inc., and Bristol
Myers Squibb.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2643
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment